EUVIMED · CrossrefJournal
Clinical Trials
ISSN 1740-7745 · SAGE Publications
Latest articles
Revisiting trial design considerations to improve efficiency of HIV-1 vertical transmission prevention efficacy trials in infants
The editor is dead, long live the editor
Automated surveillance of primary outcome reporting in clinical trials: Development and validation of a scalable screening pipeline
Evidence supporting European Medicines Agency drug approvals (2020–2023): A cross-sectional study of trial design and outcomes
Covariate adjustment in randomized clinical trials: From general theory to practical insights
A modular pipeline for natural language processing-screened human abstraction of a pragmatic trial outcome from electronic health records
From RAGs to riches: Utilizing large language models to write documents for clinical trials
Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional study
Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting
Detecting irregularities in randomized controlled trials using machine learning
Scaling and interpreting treatment effects in clinical trials using restricted mean survival time
A comparison of computational algorithms for the Bayesian analysis of clinical trials
Participant’s treatment guesses and adverse events in back pain trials: Nocebo in action?
Defining estimand for the win ratio: Separate the true effect from censoring
Assessing the current utilization status of wearable devices in clinical research
Statistical and practical considerations in planning and conduct of dose-optimization trials
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses
Risk–benefit trade-offs and precision utilities in phase I-II clinical trials
Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies
Dose optimization for cancer treatments with considerations for late-onset toxicities
The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing—Challenging the “more is better” dogma
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus
Adherence to key recommendations for design and analysis of stepped-wedge cluster randomized trials: A review of trials published 2016–2022
New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trials
What influences trust in and understanding of clinical trials? An analysis of information and communication technology use and online health behavior from the Health Information National Trends Survey
The influence of political ideology on clinical trial knowledge, invitation, and participation among adults in the United States
Informative cluster size in cluster-randomised trials: A case study from the TRIGGER trial
Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials
Barriers and facilitators to the inclusion of deaf people in clinical trials
Overall average treatment effects from clinical trials, one-variable-at-a-time subgroup analyses and predictive approaches to heterogeneous treatment effects: Toward a more patient-centered evidence-based medicine
EUVIMED